Oncology · Phase 2-3 · pulled 2026-11-06

Non-small cell lung cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of non-small cell lung cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Non-small cell lung cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Hospital Universitari Vall d'Hebron Barcelona, Spain · 26 spellings merged	31 16 completed, 15 terminated	NCT05635708 NCT04868877 NCT04129502 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05117242 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer terminated 2026-08-31 Stop reason on the record: “Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.” NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15	2026-10-29	38 NCT06881784 NCT07563738 NCT07144280 NCT06890598	81
2	Severance Hospital, Yonsei University Health System Seoul, South Korea · 18 spellings merged	31 19 completed, 12 terminated	NCT04868877 NCT04129502 NCT05786430 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05786430 Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib completed 2026-08-23 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15	2026-10-01	44 NCT04198766 NCT06881784 NCT07699328 NCT07361497	84
3	MD Anderson Cancer Center Houston, United States · 27 spellings merged	28 16 completed, 12 terminated	NCT05635708 NCT05882734 NCT04303780 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) completed 2025-10-31	2026-10-29	64 NCT05920356 NCT06881784 NCT05546268 NCT07659782	84
4	Asan Medical Center Seoul, South Korea · 14 spellings merged	28 19 completed, 9 terminated	NCT04129502 NCT06624059 NCT05882734 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) completed 2026-07-31 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT04181788 Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies completed 2026-05-13 NCT05775289 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer completed 2026-04-30	2026-09-22	47 NCT04198766 NCT05920356 NCT07361497 NCT05789082	86
5	SCRI Oncology Partners Nashville, United States · 36 spellings merged	26 13 completed, 13 terminated	NCT04868877 NCT04956692 NCT04303780 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04956692 Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) completed 2026-08-24 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer completed 2025-12-30	2026-10-01	50 NCT05920356 NCT06881784 NCT05546268 NCT07361497	73
6	Hospital Universitario 12 de Octubre Madrid, Spain · 5 spellings merged	24 16 completed, 8 terminated	NCT05635708 NCT04868877 NCT04129502 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05117242 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer terminated 2026-08-31 Stop reason on the record: “Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.” NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24	2026-10-29	38 NCT07699328 NCT07361497 NCT07563738 NCT06793215	85
7	Samsung Medical Center Seoul, South Korea · 10 spellings merged	23 15 completed, 8 terminated	NCT04868877 NCT04129502 NCT05882734 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT04248829 Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) completed 2026-04-22 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04	2026-10-01	44 NCT05920356 NCT06881784 NCT07699328 NCT07361497	86
8	Seoul National University Hospital Seoul, South Korea · 20 spellings merged	23 16 completed, 7 terminated	NCT04868877 NCT04129502 NCT05882734 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT04248829 Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) completed 2026-04-22 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26	2026-10-01	36 NCT04198766 NCT07361497 NCT06793215 NCT05789082	88
9	Beijing Cancer Hospital Beijing, China · 60 spellings merged	22 15 completed, 7 terminated	NCT04129502 NCT06624059 NCT06924606 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) completed 2026-07-31 NCT06924606 Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy terminated 2026-07-09 Stop reason on the record: “The research and development strategy was adjusted, so the research was suspended” NCT05758116 Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients completed 2026-06-30 NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT04181788 Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies completed 2026-05-13	2026-09-22	53 NCT05920356 NCT07361497 NCT06793215 NCT07144280	92
10	Shanghai Pulmonary Hospital Shanghai, China · 16 spellings merged	21 12 completed, 9 terminated	NCT05635708 NCT04129502 NCT06924606 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT06924606 Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy terminated 2026-07-09 Stop reason on the record: “The research and development strategy was adjusted, so the research was suspended” NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer terminated 2026-03-18 Stop reason on the record: “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” NCT04702009 Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer completed 2026-01-20	2026-10-29	37 NCT07874282 NCT06793215 NCT05789082 NCT07144280	89
11	Virginia Cancer Specialists Fairfax, United States · 20 spellings merged	21 14 completed, 7 terminated	NCT04868877 NCT05882734 NCT04303780 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients completed 2026-06-15 NCT06532032 A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer completed 2026-05-14 NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC completed 2026-02-08	2026-10-01	59 NCT04198766 NCT06881784 NCT05546268 NCT07659782	79
12	Henan Cancer Hospital Zhengzhou, China · 12 spellings merged	17 11 completed, 6 terminated	NCT05635708 NCT04129502 NCT05298423 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT06295432 A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) completed 2026-06-08 NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer terminated 2026-03-18 Stop reason on the record: “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) terminated 2026-01-27 Stop reason on the record: “Business Reasons”	2026-10-29	33 NCT05920356 NCT07361497 NCT07144280 NCT04487080	90
13	National Taiwan University Hospital Taipei, Taiwan · 18 spellings merged	17 13 completed, 4 terminated	NCT04129502 NCT04956692 NCT04303780 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT04956692 Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) completed 2026-08-24 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT06532032 A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer completed 2026-05-14 NCT04248829 Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) completed 2026-04-22 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26	2026-09-22	49 NCT05920356 NCT06881784 NCT07699328 NCT07361497	85
14	Hunan Cancer Hospital Changsha, China · 42 spellings merged	17 10 completed, 7 terminated	NCT05298423 NCT04205812 NCT05549037 6 trials with titles NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT04205812 Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer completed 2026-05-28 NCT05549037 Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC completed 2026-04-30 NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer terminated 2026-03-18 Stop reason on the record: “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) terminated 2026-01-27 Stop reason on the record: “Business Reasons” NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) terminated 2026-01-09 Stop reason on the record: “MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.”	2026-06-15	42 NCT05920356 NCT06793215 NCT05789082 NCT07144280	90
15	Massachusetts General Hospital Boston, United States · 6 spellings merged	16 8 completed, 8 terminated	NCT05635708 NCT05358249 NCT04129502 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation terminated 2026-09-28 Stop reason on the record: “Business reasons and not based on any safety concerns.” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) completed 2025-10-31 NCT06171789 PRO1107 in Patients With Advanced Solid Tumors terminated 2025-08-18 Stop reason on the record: “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”	2026-10-29	17 NCT06793215 NCT07491497 NCT05579366 NCT06706076	86
16	Memorial Sloan Kettering Cancer Center New York, United States · 12 spellings merged	16 7 completed, 9 terminated	NCT05635708 NCT04905316 NCT05375994 6 trials with titles NCT05635708 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer completed 2026-10-29 NCT04905316 A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer completed 2026-07-06 NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients completed 2026-06-15 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26 NCT05429320 A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) completed 2026-01-28 NCT06333678 A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) terminated 2026-01-27 Stop reason on the record: “Study closed by Amgen due to lack of enrollment”	2026-10-29	36 NCT05920356 NCT06881784 NCT05546268 NCT07659782	82
17	Complejo Hospitalario Universitario A Coruña A Coruña, Spain · 19 spellings merged	16 9 completed, 7 terminated	NCT04129502 NCT05775289 NCT05226598 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05775289 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer completed 2026-04-30 NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) terminated 2026-01-09 Stop reason on the record: “MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.” NCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer completed 2025-11-20 NCT04776447 Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) completed 2025-07-31 NCT04513925 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) completed 2025-07-31	2026-09-22	21 NCT05920356 NCT06881784 NCT07144280 NCT06452277	81
18	Hospital Clinic de Barcelona Barcelona, Spain · 12 spellings merged	16 12 completed, 4 terminated	NCT04129502 NCT05882734 NCT04303780 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04	2026-09-22	23 NCT05920356 NCT06881784 NCT06793215 NCT06452277	80
19	UPMC Hillman Cancer Center Pittsburgh, United States · 10 spellings merged	16 5 completed, 11 terminated	NCT05882734 NCT05746481 NCT05597839 6 trials with titles NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) completed 2026-07-15 NCT05746481 Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases terminated 2025-11-08 Stop reason on the record: “Decision by agent provider” NCT05597839 Study of DF9001 in Patients With Advanced Solid Tumors completed 2025-08-15 NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC completed 2025-07-09 NCT04933695 A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment terminated 2025-05-28 Stop reason on the record: “Futility” NCT05563272 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors terminated 2025-05-09 Stop reason on the record: “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”	2026-07-15	25 NCT05920356 NCT06498635 NCT07491497 NCT07397338	66
20	Dana-Farber Cancer Institute Boston, United States · 6 spellings merged	15 8 completed, 7 terminated	NCT05358249 NCT04129502 NCT05975073 6 trials with titles NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation terminated 2026-09-28 Stop reason on the record: “Business reasons and not based on any safety concerns.” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) completed 2025-10-31 NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC completed 2025-07-09	2026-09-28	32 NCT05546268 NCT04267848 NCT05579366 NCT06706076	80
21	NYU Langone Health New York, United States · 27 spellings merged	15 7 completed, 8 terminated	NCT05358249 NCT05975073 NCT04484142 6 trials with titles NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation terminated 2026-09-28 Stop reason on the record: “Business reasons and not based on any safety concerns.” NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT05807048 Daratumumab in STK11 Mutated NSCLC completed 2025-11-11 NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) completed 2025-10-31 NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC completed 2025-07-09	2026-09-28	29 NCT07659782 NCT04495153 NCT05789082 NCT07397338	74
22	City of Hope Duarte, United States · 13 spellings merged	15 8 completed, 7 terminated	NCT04303780 NCT05975073 NCT05077709 6 trials with titles NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05975073 A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors completed 2026-03-26 NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC completed 2026-02-08 NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) completed 2025-10-31 NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC completed 2025-07-09 NCT04933695 A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment terminated 2025-05-28 Stop reason on the record: “Futility”	2026-06-24	28 NCT04198766 NCT05789082 NCT04267848 NCT05830058	77
23	West China Hospital, Sichuan University Chengdu, China · 15 spellings merged	15 9 completed, 6 terminated	NCT05298423 NCT04746924 NCT04738487 6 trials with titles NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) completed 2026-06-15 NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer terminated 2026-03-18 Stop reason on the record: “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) terminated 2026-01-27 Stop reason on the record: “Business Reasons” NCT05226598 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) terminated 2026-01-09 Stop reason on the record: “MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support any registration, was issued; therefore, an abbreviated CSR was generated.” NCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer completed 2025-12-30 NCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer completed 2025-11-20	2026-06-15	40 NCT05920356 NCT07361497 NCT06793215 NCT07144280	90
24	Hospital Universitario Fundacion Jimenez Diaz Madrid, Spain · 17 spellings merged	14 7 completed, 7 terminated	NCT04868877 NCT04129502 NCT05117242 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT05117242 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer terminated 2026-08-31 Stop reason on the record: “Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT04746924 A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer terminated 2026-03-18 Stop reason on the record: “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC completed 2026-02-08	2026-10-01	22 NCT05920356 NCT07563738 NCT06452277 NCT07288177	80
25	CHU de Toulouse - Hopital Larrey Toulouse, France · 15 spellings merged	14 12 completed, 2 terminated	NCT04129502 NCT04303780 NCT05775289 6 trials with titles NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations completed 2026-09-22 NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). completed 2026-06-24 NCT05775289 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer completed 2026-04-30 NCT04484142 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) completed 2026-02-04 NCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer completed 2025-11-20 NCT04108026 Immunotherapy in Patient With Poor General Condition completed 2025-09-26	2026-09-22	16 NCT05920356 NCT06881784 NCT07361497 NCT07144280	84

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Non-small cell lung cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Shun Lu Shanghai Chest Hospital	4	NCT05015608 NCT04923945 NCT04158440 NCT04206072	PMID 42958117 BMC cancer, 2026 · High match PMID 42933639 Annals of oncology : official journal of the European Society for Medical Oncology, 2026 · High match PMID 42929693 The New England journal of medicine, 2026 · High match
2	Yongchang Zhang Hunan Cancer Hospital	3	NCT05549037 NCT04997382 NCT04003246	PMID 42988049 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026 · High match PMID 42982996 Nature medicine, 2026 · High match
3	Caicun Zhou [email protected]	3	NCT05519865 NCT05001724 NCT04900363	PMID 42988049 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026 · High match
4	Hui Liu Sun Yat-sen University	3	NCT04946019 NCT04212052 NCT04345146	PMID 42990047 Future oncology (London, England), 2026 · High match PMID 42988853 Cell death and differentiation, 2026 · High match PMID 42933457 Lancet (London, England), 2026 · Medium match
5	You Lu West China Hospital	3	NCT05215951 NCT04838548 NCT05318443	PMID 42829402 Apoptosis : an international journal on programmed cell death, 2026 · High match PMID 42824609 Advances in radiation oncology, 2026 · High match PMID 42705211 Translational oncology, 2026 · High match
6	Xiuning Le M.D. Anderson Cancer Center	2	NCT05017025 NCT04971187	PMID 42913244 Clinical lung cancer, 2026 · High match PMID 42887497 Cancer cell, 2026 · High match PMID 42806414 Cancer, 2026 · High match
7	jianyang wang National Cancer Center	2	NCT07037680 NCT05015608	PMID 42969236 The Journal of clinical investigation, 2026 · Medium match
8	Narek Shaverdian Memorial Sloan Kettering Cancer Center	2	NCT06333678 NCT04905316	PMID 42950185 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 · High match PMID 42844242 Nature communications, 2026 · High match PMID 42612834 International journal of radiation oncology, biology, physics, 2026 · High match
9	Michael DURUISSEAUX Hospices Civils de Lyon - Hôpital Louis Pradel	2	NCT04108026 NCT04111705	PMID 42929675 The New England journal of medicine, 2026 · High match PMID 42745627 Future oncology (London, England), 2026 · High match PMID 42696863 Respiratory medicine and research, 2026 · High match
10	Mariano Provencio Fundación GECP President	2	NCT04776447 NCT04512430	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.